ZYME (Biotech) Stock Valuation & Fair Value
Significantly overvaluedZYME (Biotech) trades at a current P/E of 37.0, far above its historical normal valuation, with a forward growth estimate of -24.3%. Analysts' one-year estimates have been hit 25% of the time.
How to read these numbers: the PEG ratio and current P/E versus normal P/E.
Valuation flags
- Long-term debt is over half its capital (61%)
- Overvalued far beyond its normal P/E
- Negative growth forecast
Frequently asked questions
Is ZYME overvalued?
At a current P/E of 37.0 versus its historical normal P/E of 4.1, ZYME trades far above its typical valuation. tickerseer currently rates it significantly overvalued.
What is ZYME's fair value and PEG?
ZYME trades at a current P/E of 37.0 against a historical normal P/E of 4.1, a forward growth estimate of -24.3%.
Has tickerseer's rating of ZYME changed?
tickerseer's rating has been significantly overvalued since 2026-11-07.
Industry: Biotech. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and an AI research note where we have one. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.